Navigation Links
New genomics research investigates metastatic childhood cancers
Date:2/22/2011

Vancouver, BC In a project supported by Genome BC, a Vancouver pediatric pathologist at the BC Cancer Agency/University of British Columbia is leading the team that will explore the genomes (DNA) of four of the most challenging childhood cancers known. Dr. Poul Sorensen and his colleagues in the Canadian Pediatric Cancer Genome Consortium hope to find the link between primary and metastatic tumours using revolutionary genomics technology and a highly skilled consortium of scientists and clinicians.

Most cancer deaths are not caused by the primary disease; rather, it is the invasion and spreading of mutated cells to distant sites in the body (metastasized tumours) that tend to give a poor prognosis for the patient. Using next generation sequencing to rapidly scan the DNA of primary tumours, metastatic tumours and normal tissue, Sorensen and his team are discovering fundamental differences between primary and metastatic disease tissue. This knowledge will not only help to determine how to better treat childhood cancers but more importantly give insight into how to prevent tumours from metastasizing to other parts of the body. If the team can determine which genetic mutations cause the disease to spread, then appropriate therapies can hopefully be designed and/or re-directed to prevent metastasis.

"There is little known about metastatic disease in either pediatric or adult cancer," says Sorensen. "Our biggest challenge to improving survival is to understand the biology of metastatic disease and how to target it." If the team can determine all possible genetic mutations and study a cohort of samples, they can identify the common mutations and determine which mutation is in fact driving the spread of disease. The motivation for the project stems from a lack of understanding in the background mutation of tumours from primary to metastatic progression. "It is imperative to understand metastases and this is an area that has not been well researched on a genomic level internationally," Sorensen adds.

The team will focus on medulloblastoma (brain cancer), metastatic osteosarcoma (bone cancer) and two other types of pediatric brain tumours to uncover genetic abnormalities that direct tumour cells to spread or become resistant to treatment. They will examine and directly compare the genetic signature of each of these diseases in primary tumour cells and tumour cells that have metastasized or relapsed. These studies will produce a first-time view of the tumour genomes in these diseases. This insight not only provides immediate potential for improving tailored therapies for children with these lethal cancers, but will enable the future development of new drugs for patients who otherwise have limited options for treatment.

"Genome BC is thrilled to be funding this essential and ground-breaking work. Our hope is that the results from this research will impact not only on childhood cancers but to shed light on the link between primary and metastatic tumours for all cancer patients," says Dr. Alan Winter, President and CEO of Genome BC.

"Having the genetic, biological and clinical expertise in Vancouver makes this an ideal place to lead this research. The research team has access to rare samples and can tap into an international network to allow for a quick and easy liaison from bench to bedside," says Sorensen. The mutational landscape of cancer cells is nearly impossible to find with only one tumour to analyze; however, with a national network and international linkages the team can begin to make the imperative connections between normal and mutated genes across a larger group of cases.

The $2.8 million (CDN) research project is also funded by the Canadian Institutes of Health Research (CIHR), Genome Canada, Genome Quebec and the C17 Research Network.


'/>"/>

Contact: Jennifer Boon
jboon@genomebc.ca
778-327-8374
Genome BC
Source:Eurekalert

Related medicine news :

1. Promise of genomics research needs a realistic view
2. NHGRI charts course for the next phase of genomics research
3. La Jolla Institute to develop San Diegos first center for RNAi genomics research
4. Radiation pharmacogenomics identifies biomarkers that could personalize cancer treatment
5. St. Jude researcher receives grant to focus on cancer pharmacogenomics in children
6. Genentech uses Complete Genomics human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature
7. Lawrence Berkeley National Laboratory and OpenHelixTM Announce an Updated Free Tutorial Suite for VISTA: Tools for Comparative Genomics
8. Compound used to block cholesterol could also kill breast cancer, MU researcher finds
9. Queens University researcher connects cannabis use and sexual dysfunction
10. Research uncovers a secret society connecting through the Internet
11. $1.9 million NIH grant supports research in the most common soft tissue tumor in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... , ... August 18, 2017 , ... ... financial planning assistance that serves communities throughout southern Florida, is working to support ... scholarship assets to children from low income families. , The Take Stock In ...
(Date:8/18/2017)... ... August 18, 2017 , ... With over 16,000 active patients, ... replacement therapy and integrative medicine, has become a frontrunner for people seeking help ... menopause, andropause, thyroid disorder and adrenal insufficiencies. , Founded in 2003 by ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Our Mountains to Climb: A ... a couple that grew stronger together through the faith they shared to overcome struggles ... is the creation of published author, Barbara J. Corcoran, a retired teacher and happily ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... marketers of high-quality anti-aging skincare solutions, recently announced the launch of ... products are an affordable, yet effective alternative to expensive plastic surgery or in-patient ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... a new location in Goldsboro, NC to its family of practices. Residents of ... Associates’ trademark starting August 15, 2017. , Riccobene Associates Family Dentistry, founded ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... 31, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), has been ... Michigan by Crain,s Detroit Business . ... companies by three-year revenue growth. This year,s edition measures growth ... To view the complete list, visit crainsdetroit.com/awards/fast_50/2017 .  ... incredible triumph," said Phil Hagerman , CEO and chairman ...
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
(Date:7/27/2017)... Services, Inc. (NYSE: WST ) today announced ... financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record high, ... constant currency (organic) grew by 3.9%. ... in the prior-year quarter. Second-quarter 2017 adjusted diluted EPS ...
Breaking Medicine Technology: